Patrick Harrison Carroll Sells 23,726 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total transaction of $830,410.00. Following the sale, the insider owned 181,861 shares in the company, valued at $6,365,135. The trade was a 11.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $32.61 on Thursday. The company has a 50-day simple moving average of $27.52 and a 200-day simple moving average of $26.46. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $7.55 billion, a PE ratio of -362.37, a P/E/G ratio of 47.12 and a beta of 2.37. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. During the same period in the prior year, the firm posted $0.20 EPS. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HIMS. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a report on Tuesday, May 12th. Barclays lifted their price objective on Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday, June 17th. Leerink Partners upped their target price on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. TD Cowen dropped their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Finally, Bank of America dropped their price target on Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a research report on Tuesday, May 26th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $29.37.

Institutional Trading of Hims & Hers Health

Large investors have recently modified their holdings of the business. Flagship Harbor Advisors LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $28,000. Binnacle Investments Inc acquired a new stake in Hims & Hers Health during the 3rd quarter valued at $28,000. Bogart Wealth LLC grew its holdings in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the first quarter worth $30,000. Finally, Greenline Wealth Management LLC purchased a new position in Hims & Hers Health during the fourth quarter worth $36,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.